Clinical Trial Update: Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial comparing neoadjuvant chemo-endocrine therapy to chemotherapy alone in ER-positive, HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer Female | Phase 3 | Status: COMPLETED